16628-26-5

Basic information

• Product Name: N-(6-bromobenzo[d]thiazol-2-yl)acetamide
• Synonyms: N-(6-bromobenzo[d]thiazol-2-yl)acetamide
• CAS NO: 16628-26-5
• Molecular Formula: C₉H₇BrN₂OS
• Molecular Weight: 271
• Mol File: 16628-26-5.mol

Chemical Properties

• Appearance: /
• Density: 1.743±0.06 g/cm3(Predicted)
• PKA: 10.28±0.70(Predicted)
• CAS DataBase Reference: N-(6-bromobenzo[d]thiazol-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-bromobenzo[d]thiazol-2-yl)acetamide(16628-26-5)
• EPA Substance Registry System: N-(6-bromobenzo[d]thiazol-2-yl)acetamide(16628-26-5)

Safety Data

• Hazardous Substances Data: 16628-26-5(Hazardous Substances Data)

Usage

General Description

N-(6-bromobenzo[d]thiazol-2-yl)acetamide is an organic compound with the chemical formula C10H8BrN3OS. It is a derivative of benzo[d]thiazole, which is a heterocyclic compound containing both benzene and thiazole rings. The compound contains a bromine atom and an acetamide group, making it useful for various organic synthesis reactions. It has potential applications in the pharmaceutical and agrochemical industries due to its structural properties and potential biological activities. N-(6-bromobenzo[d]thiazol-2-yl)acetamide may also be used as a building block in the synthesis of other complex organic molecules.

Upstream product

• 2646-30-2 1-(4-bromophenyl)thiourea 
• 106-40-1 4-bromo-aniline 
• 15864-32-1 2-amino-6-bromobenzothiazole 
• 75-36-5 acetyl chloride 
• 20358-05-8 7-bromo-1,3-benzothiazol-2-amine 
• 108-24-7 acetic anhydride 

Downstream Products

• 885069-14-7 N-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-benzothiazol-2-yl]acetamide 
• 1112982-67-8 N-(6-(3-fluoro-4-methoxyphenyl)benzo[d]thiazol-2-yl)acetamide 
• 1112980-15-0 N-(7-(3-fluoro-4-methoxyphenyl)-1,3-benzothiazol-2-yl)acetamide 
• 1204741-92-3 6-phenyl-N-acetyl-2-aminobenzo[d]thiazole 
• 1192831-42-7 N-{6-[4-methyl-3-(methylsulfonyl)phenyl]-1,3-benzothiazol-2-yl}acetamide 

Relevant articles and documents

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K

PI3 kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration and differentiation. The PI3 Kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations and PTEN p

Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors

Abstract Vismodegib is the first FDA approved cancer therapy based on inhibition of aberrant hedgehog signaling. Like most cancer therapies, vismodegib suffered from resistance, even during clinical development. Numerous reports demonstrated that simultan

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

Medicine with necrocytosis inhibitory activity and application thereof

The invention provides a medicine with the necrocytosis inhibitory activity. The medicine with the necrocytosis inhibitory activity contains one or two of the following compounds. The invention further provides application of the medicine with the necrocy

MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or behaviors mediated by an mTOR kinase and/or one or more PI3K enzyme, are provided. Such diseases and disorder include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Synthesis of N-(6-Arylbenzo[d]thiazole-2-acetamide derivatives and their biological activities: An experimental and computational approach

A new series of N-(6-arylbenzo[d]thiazol-2-yl)acetamides were synthesized by C-C coupling methodology in the presence of Pd(0) using various aryl boronic pinacol ester/acids. The newly synthesized compounds were evaluated for various biological activities like antioxidant, haemolytic, antibacterial and urease inhibition. In bioassays these compounds were found to have moderate to good activities. Among the tested biological activities screened these compounds displayed the most significant activity for urease inhibition. In urease inhibition, all compounds were found more active than the standard used. The compound N-(6-(p-tolyl)benzo[d]thiazol-2-yl)acetamide was found to be the most active. To understand this urease inhibition, molecular docking studies were performed. The in silico studies showed that these acetamide derivatives bind to the non-metallic active site of the urease enzyme. Structure-activity studies revealed that H-bonding of compounds with the enzyme is important for its inhibition.

Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules

DYRK1A has emerged as a potential target for therapies of Alzheimer's disease using small molecules. On the basis of the observation of selective DYRK1A inhibition by firefly d-luciferin, we have explored static and dynamic structural properties of fragment sized variants of the benzothiazole scaffold with respect to DYRK1A using X-ray crystallography and NMR techniques. The compounds have excellent ligand efficiencies and show a remarkable diversity of binding modes in dynamic equilibrium. Binding geometries are determined in part by interactions often considered "weak", including "orthogonal multipolar" types represented by, for example, F-CO, sulfur-aromatic, and halogen-aromatic interactions, together with hydrogen bonds that are modulated by variation of electron withdrawing groups. These studies show how the benzothiazole scaffold is highly promising for the development of therapeutic DYRK1A inhibitors. In addition, the subtleties of the binding interactions, including dynamics, show how full structural studies are required to fully interpret the essential physical determinants of binding.

Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ

Phosphoinositide 3-kinase γ (PI3Kγ) is an attractive target to potentially treat a range of disease states. Herein, we describe the evolution of a reported phenylthiazole pan-PI3K inhibitor into a family of potent and selective benzothiazole inhibitors. U

Enhanced treatment regimens using mTor inhibitors

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.